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Introduction
The human epidermal growth factor receptor (HER) family
of receptor tyrosine kinases comprises four members:
epidermal growth factor receptor (EGFR; also termed
HER1 or ErbB1), HER2 (also termed ErbB2 or neu),
HER3 (ErbB3), and HER4 (ErbB4). Collectively, these are
also referred to as the ErbB receptors. Evidence from
experimental systems and from primary human breast
tumors implicates the ErbB signaling network in the
pathogenesis of breast cancer. In particular, amplification
of HER2 is associated with an aggressive tumor
phenotype that is characterized by relatively rapid tumor
growth, metastatic spread to visceral sites, and drug
resistance. Targeted blockade of ErbB signaling with
trastuzumab, a humanized monoclonal antibody directed
at the HER2 receptor, has been shown to improve survival
in women with HER2-positive, advanced breast cancer.
Recent data also indicate that upregulation of the ErbB
receptors may mediate endocrine resistance, due to
crosstalk between the ErbB and estrogen receptor (ER)
signal transduction pathways.
Several orally bioavailable, low-molecular-weight tyrosine
kinase inhibitors (TKIs), directed at members of the ErbB
family, are now in clinical development, both as single
agents and in combination with either chemotherapy or
hormonal therapy. These agents may be associated with a
more favorable toxicity profile than traditional cytotoxic
chemotherapy.
Rationale for targeting ErbB receptors in
breast cancer
ErbB receptors are composed of an extracellular ligand
binding domain, a single transmembrane domain, and an
intracellular domain with tyrosine kinase activity [1]. More
than 10 ligands have been identified (Fig. 1). Upon ligand
binding the extracellular domain undergoes conformational
change, allowing the formation of homodimers or
heterodimers with other members of the ErbB family. In
turn, dimerization induces tyrosine phosphorylation of
specific residues in the intracellular domain that serve as
docking sites for adaptor proteins and downstream
effectors [2]. As a result, activation of the phosphotidyl-
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Abstract
Over the past several years many advances have been made in our understanding of critical
pathways involved in carcinogenesis and tumor growth. These advances have led to the investigation
of small molecule inhibitors of the ErbB family of receptor tyrosine kinases across a broad spectrum
of malignancies. In this article we summarize the rationale for targeting members of the ErbB family in
breast cancer, and review the preclinical and clinical data for the agents that are furthest in
development. In addition, we highlight directions for future research, such as exploration of the
potential crosstalk between the ErbB and hormone receptor signal transduction pathways,
identification of predictive markers for tumor sensitivity, and development of rational combination
regimens that include the tyrosine kinase inhibitors.
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inositol 3-kinase (PI3K) and mitogen-activated protein
kinase pathways occurs, leading to cell proliferation and
survival (Fig. 2). Each of the ErbB receptors is thought to
recruit a unique combination of effector molecules. The
range of possible homodimers and heterodimers, along
with the multitude of downstream effectors, is thought to
account for the signaling diversity of the ErbB network.
EGFR is overexpressed in 16–48% of human breast
cancers. Several groups have reported an association
between EGFR expression and poor prognosis [3–5]. In
addition, the constitutively active, tumorigenic EGFR vIII
variant has been reported to be present in up to 78% of
breast carcinomas [6]. Data from animal models also
support a role for EGFR in breast cancer; for example,
overexpression of the EGFR ligand transforming growth
factor-α results in mammary carcinomas in mice [7].
HER2 is overexpressed in 25–30% of all human breast
carcinomas; high levels of expression are generally
associated with gene amplification [8]. Unlike other ErbB
receptors, HER2 does not have a known ligand but
instead functions as the preferred heterodimerization
partner of all other ErbB receptors [2]. In preclinical
models, HER2 overexpression induces the malignant
transformation of NIH/3T3 cells, and transgenic mice that
carry an activated HER2 oncogene develop multiple
synchronous breast adenocarcinomas [9]. In the clinic,
HER2 has emerged as a highly important prognostic
factor for relapse and overall survival in women with
primary breast cancer [8]. Trastuzumab, a monoclonal
antibody directed against HER2, is active both as a single
agent and in combination with chemotherapy in women
with HER2-positive breast cancer [9–11]. When
compared with chemotherapy alone, combinations of
trastuzumab plus chemotherapy lead to higher response
rates, longer time to disease progression, and an
improvement in overall survival [10]. There appears to be
little question that signaling through HER2 is crucial for
the development, growth, and survival of breast tumors.
The roles of HER3 and HER4 in breast cancer are less
well defined. HER3 is overexpressed in 15–35% of
primary breast tumors and may be associated with
decreased local control and overall survival [5,12].
Although the clinical data are limited, they are consistent
with the known role of HER3 as a critical partner for both
EGFR (ErbB1) and HER2 in terms of signaling through
the PI3K pathway [13]. In contrast, activation of HER4
appears to be both necessary and sufficient for
antiproliferative and differentiation responses in human
breast cancer cells in vitro, perhaps because of the
decreased capacity of HER4 to activate proliferation via
the Ras/Raf/mitogen-activated protein kinase signal
transduction pathway [14]. Consistent with these
observations, in small studies HER4 overexpression
(found in approximately 10% of breast tumors) appeared
Figure 1
The ErbB family of receptor tyrosine kinases. Known ligands are listed
above each receptor. Human epidermal growth factor receptor (HER)2
has no known ligand. The kinase domain of HER3 is inactive. ErbB
receptors can also be activated by nonconventional agonists, such as
decorin and Cripto-1, which are not shown here. AR, amphiregulin;
BTC, betacellulin; EGF, epidermal growth factor; EGFR, epidermal
growth factor receptor; EPR, epiregulin; HB-EGF, heparin-binding
epidermal growth factor; NRG, neuregulin; TGF, transforming growth
factor.
Figure 2
The ErbB signaling pathway. Ligand binding induces dimerization,
leading to activation of the intracellular tyrosine kinase. Upon auto-
phosphorylation and cross-phosphorylation of the receptor complex,
key downstream effectors are recruited. FasL, Fas ligand; FKHR,
forkhead in rhabdomyosarcoma; Grb, growth factor receptor-bound
protein; GSK, glycogen synthase kinase; MAPK, mitogen-activated
protein kinase; MEK, MAPK kinase; mTOR, molecular target of
rapamycin; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase
and tensin homolog deleted on chromosome 10; SOS, son-of-
sevenless guanine nucleotide exchange factor.206
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to be associated with low nuclear grade, low proliferative
index, and increased survival [5,15].
Small molecule tyrosine kinase inhibitors
A number of ErbB receptor inhibitors are in clinical
development (Tables 1 and 2); none have received US
Food and Drug Administration approval for the treatment
of breast cancer. These small molecules compete with
ATP for binding to the kinase domain of the receptor. TKIs
have several potential advantages over monoclonal
antibodies. First, they are orally bioavailable and generally
well tolerated. Second, they appear active against
truncated forms of the EGFR and HER2 receptors (EGFR
vIII and p95, respectively) in vitro [16,17]. Third, their
Table 1
Small molecule inhibitors of ErbB tyrosine kinases in clinical development
EGFR IC50 HER2 IC50 HER4 IC50
Agent (µmol/l) (µmol/l) (µmol/l) Reversible/irreversible Source
Gefitinib (Iressa™, ZD1839) 0.02 3.7 NR Reversible AstraZeneca
Erlotinib (Tarceva™, OSI-774) 0.02 3.5 NR Reversible Genentech/Roche
EKB-569 0.038 1.2 NR Irreversible Wyeth-Ayerst
TAK-165 NR 0.006 NR NR Takeda
GW572016 0.011 0.009 NR Reversible GlaxoSmithKline
PKI-166 0.02 0.1 NR Reversible Novartis
AEE-788 0.002 0.006 0.16 Reversible Novartis
CI-1033 0.0008 0.019 0.007 Irreversible Pfizer
AEE-788 also inhibits KDR with a 50% inhibitory concentration (IC50) of 0.077 µmol/l. NR, not reported. EGFR, epidermal growth factor receptor;
HER, human epidermal growth factor receptor.
Table 2
Small molecule ErbB inhibitors in breast cancer: clinical data
Phase of development 
Agent in breast cancer Adverse affects Clinical activity in breast cancer
Gefitinib Phase II Rash, diarrhea, nausea, vomiting, elevated  1 PR, 2 SD in 63 patients [19]
transaminases; 0.3–2% risk for interstitial  2 PR, 3 SD in 19 patients [20]
lung disease [18] 1 MR, 3 SD in 31 patients [21]
Erlotinib Phase II: MBC Rash, diarrhea, nausea, fatigue, headache,  1 PR, 3 SD (12 weeks, 16 weeks, and 
elevated transaminases >28 weeks) in 47 patients [22]
0 PR in 18 patients [23]
EKB-569 Phase I: advanced solid tumors Diarrhea, rash, nausea, vomiting, stomatitis,  NR
anorexia [24]
TAK-165 Phase I: HER2-positive MBC NR NR
GW572016 Phase II: MBC, either  Diarrhea, nausea, fatigue, rash, headache,  4 PR in trastuzumab-refractory disease 
HER2-positive or -negative elevation of transaminases [25]
3 PR, 5 SD (12–36+ weeks) in 44 
patients with trastuzumab-refractory 
disease [27]
PKI-166 Phase I: advanced cancer  Nausea, vomiting, diarrhea, fatigue, myalgia,  NR
completed  rash, elevation of transaminases [26]
No longer under clinical 
development
AEE-788 Phase I: advanced solid tumors NR NR
CI-1033 Phase II: MBC Nausea, vomiting, asthenia, diarrhea, rash,  No objective responses reported to date 
mucositis, hypersensitivity,  in phase I trials, but 1 SD [16]
thrombocytopenia
HER, human epidermal growth factor receptor; MBC, metastatic breast cancer; MR, minor response; NR, not reported; PR, partial response; SD,
stable disease (>6 months unless otherwise stated).207
small size may allow them to penetrate sanctuary sites,
such as the central nervous system. Finally, by taking
advantage of the homology between kinase domains of
ErbB receptors, TKIs can be developed to target more
than one member of the receptor family simultaneously.
Epidermal growth factor receptor inhibitors
The reversible EGFR inhibitors gefitinib (Iressa™;
AstraZeneca, London, UK) and erlotinib (Tarceva™;
Genentech, South San Francisco, CA, USA) are furthest
in the course of development. Gefitinib is approved in the
USA for the treatment of non-small-cell lung cancer
(NSCLC), based on clinical trials that have demonstrated
activity in a relatively small percentage of patients [18].
Both gefitinib and erlotinib have activity against multiple
breast cancer cell lines in vitro and in xenograft models. In
clinical trials the most commonly reported adverse effects
were grade 1 or 2 rash, diarrhea, asthenia, nausea, and
vomiting. However, neither gefitinib nor erlotinib has
demonstrated significant single-agent activity against
refractory metastatic breast cancer. Across three phase II
studies of gefitinib, only three partial responses and eight
patients with stable disease lasting 6 months or longer
were observed among a total of 113 patients [19–21].
Two phase II studies of erlotinib have also been
disappointing, with only one partial response seen among
87 patients treated [22,23]. It is unclear whether response
rates would have been higher in a less heavily pretreated
patient population. Of interest, there was no correlation
between EGFR expression and response, but with such a
small number of responses, any conclusion about the
relationship between response and expression is quite
limited.
EKB-569 is an irreversible EGFR inhibitor that is in phase I
trials for advanced solid tumors [24]. Response data in
breast cancer have not been published to date. Given the
experience with gefitinib and erlotinib, it seems unlikely
that monotherapy with EKB-569 will have a substantial
degree of activity in an unselected and heavily pretreated
group of women with advanced breast cancer.
Dual kinase inhibitors
Promiscuous heterodimerization of ErbB receptors allows
for signaling through a variety of receptor–receptor
combinations. Thus, one potential mechanism of
resistance to agents targeted against a single ErbB
receptor (e.g. gefitinib or trastuzumab) is upregulation of
other members of the receptor family. Consequently, dual
kinase inhibitors against EGFR and HER2 could
theoretically have activity in resistant tumors, as well as in
tumors that have not previously been exposed to an EGFR
or HER2 inhibitor. Indeed, in animal models simultaneous
blockade of both receptors has been shown to result in
increased cell kill compared with blockade of either
receptor alone.
Two dual TKIs have been evaluated in phase I trials:
GW572016 and PKI-166. The safety, tolerability, and
pharmacokinetics of both drugs have been characterized
[25,26]. Among patients with advanced breast cancer
treated with GW572016, there have been seven partial
responses reported thus far in women with trastuzumab-
refractory disease [25,27]. Of patients treated with
GW572016, 25% developed grade 1 or 2 rash. Mild
gastrointestinal symptoms were also seen, with 21%
having grade 1 or 2 nausea and vomiting and 27% having
grade 1 or 2 diarrhea. Phase II trials of GW572016 in
patients with metastatic breast cancer are ongoing. PKI-
166 is no longer under development because of toxicity
concerns. However, AEE788, a compound that targets
EGFR, HER2, and the vascular endothelial growth factor
receptor, is currently under evaluation in phase I trials of
advanced solid tumors, colorectal cancer, and
glioblastoma multiforme. Based on its mechanism of
action, this agent could have promise in the treatment of
breast cancer.
Pan-ErbB Inhibitors
CI-1033 is an irreversible pan-erbB inhibitor that
covalently binds to the ATP binding site of the intracellular
kinase domain. In mouse xenograft models, a variety of
irreversible inhibitors have demonstrated superior
antitumor activity in comparison with reversible inhibitors.
Whether irreversible inhibitors will offer any advantages in
humans is unknown. CI-1033 has been studied in phase I
trials of heavily pretreated patients with a variety of solid
tumors, including more than 10 patients with breast
cancer. One patient has achieved stable disease for more
than 25 weeks, but objective responses have not yet been
reported [16,28–30]. Like the other TKIs, CI-1033 is
associated with grade 1–2 diarrhea, rash, nausea, and
vomiting. However, it has also been associated with a
28% rate of thrombocytopenia. Rarely, hypersensitivity
reactions have been observed at doses in excess of 500
mg. A phase II trial of CI-1033 in patients with metastatic
breast cancer recently reached its accrual goal.
Future directions
Targeting ‘targeted therapy’
Although the clinical results with EGFR inhibitors in
patients with breast cancer have been disappointing to
date, it has been argued that trastuzumab would have
been considered an inactive drug if studied in unselected
populations of patients with breast cancer. Like
trastuzumab, it is possible that TKIs will be highly active in
selected patient populations. However, it is unlikely that
prediction of sensitivity to TKIs will be as straightforward
as was the case for trastuzumab; thus far, the data
suggest that the presence of receptor overexpression
does not adequately predict response. Recent studies
have demonstrated that many patients with NSCLC who
benefit from gefitinib have somatic mutations in the kinase
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domain of the EGFR [31,32]. It is unknown whether breast
tumors contain similar mutations, or whether such
mutations predict response to EGFR inhibitors. Other
groups have focused on predictors of response to dual
and pan-ErbB TKIs. There is preliminary evidence that
response to these agents is associated with high levels of
EGFR, HER2, pAkt, and pErk at baseline, whereas
disease progression is associated with persistently high
levels of pAkt and pErk despite treatment. Of interest, in
one study [33] high levels of pAkt and pErk at baseline
predicted response to TKIs but not to trastuzumab.
Furthermore, although monoclonal antibodies and TKIs
ostensibly inhibit the same targets, there appear to be
substantial differences in their clinical activity [34]. For
example, cetuximab, a monoclonal antibody directed
against EGFR, has single-agent activity against colorectal
cancer, whereas gefitinib and erlotinib do not [34,35].
Moreover, although combinations of TKIs with
chemotherapy have not yet been demonstrated to improve
outcomes, trastuzumab-based regimens are associated
with improved survival in metastatic breast cancer [10]. In
the setting of advanced colorectal cancer, the addition of
cetuximab to irinotecan is associated with increased
response rates and time to progression compared with
irinotecan alone [36]. It is not yet clear what accounts for
these observed differences, but the differences do raise
questions as to the mechanisms by which monoclonal
antibodies and TKIs function to inhibit tumor growth
and/or result in cell death.
Crosstalk between signal transduction pathways
Importantly, data from in vitro models and from
retrospective series in women with breast cancer suggest
that both EGFR and HER2 overexpression confer
resistance to hormonal therapy [2]. Crosstalk between ER
and ErbB pathways has been postulated to occur via
multiple mechanisms, including upregulation of EGFR and
HER2 expression by tamoxifen, ligand-independent
signaling of ER via PI3K, and modulation of coactivators of
ER via downstream effectors of the ErbB pathway [37]. In
preclinical models, co-blockade of the EGFR and ER
pathways with gefitinib and either tamoxifen or fulvestrant
resulted in restoration of tamoxifen sensitivity and delay of
resistance to estrogen deprivation in HER2-over-
expressing breast tumors [38]. Based on these data,
several phase II trials of gefitinib with hormonal therapy,
and a phase III trial of letrozole ± the dual inhibitor
GW572016 are ongoing in women with ER-positive
metastatic breast cancer.
Combining tyrosine kinase inhibitors with
chemotherapy, radiotherapy, and other targeted agents
Enthusiasm for adding EGFR inhibitors to chemotherapy
has waned slightly since the results of two randomized
studies in NSCLC (Iressa NSCLC Trials Assessing
Combination Therapy [INTACT] 1 and 2) were reported
[18]. In these trials, the addition of gefitinib to cytotoxic
chemotherapy did not improve progression-free or overall
survival. Nevertheless, given the success of combination
regimens with trastuzumab and chemotherapy in
metastatic breast cancer, and the preclinical data showing
synergy between TKIs and chemotherapy, it is still
reasonable to study chemotherapy-based regimens.
Several ongoing phase II and phase III trials in metastatic
breast cancer utilize gefitinib, erlotinib, or GW572016 in
combination with chemotherapy. Alternatively, combining
antibody-based therapy (e.g. C225 or trastuzumab) with
TKIs may allow for more complete blockade of ErbB-
mediated signal transduction pathways, and thereby delay
or overcome drug resistance. This strategy is being
employed in a phase II study of trastuzumab and gefitinib.
TKIs are also potent radiosensitizers [39]. Their small size
may allow for improved penetration into tumors, which,
combined with concurrent radiation, could result in
improved cell kill. There are no trials in breast cancer
utilizing this approach, but it is being studied in phase I/II
trials in primary brain tumors.
Chemoprevention
There has been interest in developing novel
chemoprevention strategies that have an impact upon the
incidence of hormone receptor negative tumors. Lu and
coworkers [40] recently reported that gefitinib delayed the
development of ER-negative tumors in transgenic mice
engineered to overexpress HER2. In women with ductal
carcinoma  in situ, gefitinib reduced proliferation, as
measured by Ki67 [41]. It is too early to know whether
these results will translate into improved outcomes in
women at high risk for developing breast cancer. Although
the toxicity profile of the existing TKIs may be reasonable
in the setting of metastatic disease, it is unclear whether
protracted use of these agents would be tolerated by
otherwise healthy women.
Conclusion
The ErbB receptor family represents an attractive target
for cancer therapy. A number of TKIs that inhibit EGFR,
HER2, HER4, or combinations thereof are in clinical
development. The challenge that lies ahead is to identify
those patients who will benefit from targeting of the ErbB
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receptor family, and to determine how best to integrate
these compounds into the armamentarium of both
standard and novel treatments for breast cancer. It may be
most fruitful to combine agents that target multiple
neoplastic pathways, with the goal of producing highly
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